Bristol Myers' $10B Cancer Drug Opdivo Scores Expanded Use FDA Approval For Lung Cancer In Pre And Post-Surgery Setting
Opdivo (nivolumab) for resectable non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) ...
GlobalData on MSN21h
BMS receives FDA approval for Opdivo to treat NSCLC
Bristol Myers Squibb (BMS) has received approval from the US Food and Drug Administration (FDA) for Opdivo to treat adults ...
Cure Today12h
Opdivo with Abraxane May Expand Therapeutic Opportunities For MIBC
Patients with muscle-invasive bladder cancer experienced safe medical and surgical treatment with the NURE-combo.
pharmaphorum22h
FDA approval give BMS an edge in NSCLC treatment
In 2023, BMS received a similar approval across the pond. The National Institute for Health and Care Excellence (NICE) ...
FiercePharma1d
BMS' Opdivo joins the perioperative lung cancer treatment ring with key FDA approval
Hot on the tail of AstraZeneca’s Imfinzi, Bristol Myers Squibb’s PD-1/L1 inhibitor Opdivo has expanded its non-small cell lung cancer (NSCLC) net with an ...
Cancer Therapy Advisor19h
Opdivo Approved in Neoadjuvant and Adjuvant Setting for Resectable NSCLC
The FDA has approved Opdivo (nivolumab) as neoadjuvant and adjuvant treatment for adults with resectable NSCLC.
BioSpace20h
BMS Wins FDA Nod for Perioperative Opdivo Regimen in NSCLC
Opdivo’s approval for patients with resectable non-small cell lung cancer comes as the regulator recently raised concerns of ...
The American Journal of Managed Care18h
Nivolumab Approved as Neoadjuvant, Adjuvant Therapy for NSCLC by FDA
The approval came days before the FDA’s expected deadline and makes this the only PD-1 inhibitor approved for resectable ...
The Pharma Letter23h
FDA approves Opdivo for lung cancer before and after surgery
Bristol Myers Squibb has received FDA approval for Opdivo (nivolumab) combined with chemotherapy as a perioperative treatment ...
Pharmaceutical Technology4d
Keytruda and Opdivo: a decade review
PD-1 inhibitors have revolutionised cancer treatment over the last decade, with their success attributed to Keytruda and ...
Cure Today1d
FDA Approves Presurgical, Postsurgical Opdivo for NSCLC
The Food and Drug Administration has approved Opdivo before and after surgery for some with non-small cell lung cancer.
Bristol-Myers wins FDA nod for Opdivo lung cancer indication
Bristol-Myers Squibb (BMY) wins FDA nod to expand the U.S. label for its blockbuster immunotherapy Opdivo in lung cancer.